Related Experiment Video

Updated: Jun 22, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Recognising pneumonia burden through prevention

Carlos G Grijalva1

  • 1Department of Preventive Medicine, Vanderbilt University School of Medicine, Nashville, TN 37212, USA. carlos.grijalva@vanderbilt.edu

Vaccine
|June 23, 2009
PubMed

Insights

Routine childhood immunisation with the seven-valent pneumococcal conjugate vaccine (PCV7) significantly reduced pneumonia hospitalisations in children under two years old. This vaccine demonstrated a direct impact on decreasing both all-cause and pneumococcal pneumonia rates.

Area of Science:

  • Pediatrics
  • Infectious Diseases
  • Vaccinology

Background:

  • Streptococcus pneumoniae causes significant childhood illnesses, including pneumonia, meningitis, and bacteremia.
  • Pneumonia is a leading cause of mortality in children under five years old globally.
  • Invasive pneumococcal diseases (IPDs) pose a substantial public health burden.

Purpose of the Study:

  • To evaluate the impact of routine immunisation with the seven-valent pneumococcal conjugate vaccine (PCV7) on pneumonia hospitalisations in young children.
  • To assess the effectiveness of PCV7 in reducing all-cause and pneumococcal pneumonia rates.
  • To determine the direct effect of PCV7 on pediatric pneumonia hospitalisations.

Main Methods:

  • Observational study analyzing hospitalisation data before and after PCV7 implementation.
  • Comparison of pneumonia hospitalisation rates in children under two years old.
  • Statistical analysis to determine the reduction in all-cause and pneumococcal pneumonia rates.

Main Results:

  • A substantial decline in pneumonia-related hospitalisations was observed in children under two years old after PCV7 introduction.
  • Rates of all-cause pneumonia hospitalisations decreased by 39%.
  • Rates of pneumococcal pneumonia hospitalisations decreased by 65% in the target age group.

Conclusions:

  • Routine immunisation with PCV7 has a direct and significant impact on reducing pneumonia hospitalisations in infants and young children.
  • PCV7 is an effective public health intervention for preventing severe pneumococcal disease and pneumonia in children.
  • The findings support the continued use and expansion of pneumococcal conjugate vaccines in childhood immunisation programs.

Related Concept Videos

Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...